Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

29 of 40

Richard Pops, chairman and CEO of Alkermes

Richard Pops was fired up during our lunch with him during the J.P. Morgan Healthcare Conference. Alkermes ($ALKS) has potential blockbuster psychiatric drugs in its pipeline, led by the Ireland-based company's long-acting version of Abilify, ALKS-9070, in late-stage development. Imagine an Alkermes where the handsome income stream from Johnson & Johnson's ($JNJ) Risperdal Consta seems quaint? Referencing his bigger Boston-area neighbors, Pops said: "We're going to build a Biogen or a Vertex."